drugset / Trial / NCT03583658

Efficacy and Safety Study of New Ambroxol Hardboiled Lozenges in Acute Pharyngitis

NCT03583658

Phase 3 Completed 390 enrolled Sanofi
RandomizedParallel-groupDouble-blindTreatment

Summary

Primary Objective: To assess the efficacy of the new hard boiled Ambroxol lozenges 20 mg for the relief of sore throat pain in patients with acute pharyngitis. Secondary Objective: To assess the safety of the new hard boiled Ambroxol lozenges 20 mg in patients with acute pharyngitis.

Timeline

Start
2018-06-30
Primary completion
2018-09-02
Completion
2018-09-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ambroxol Small molecule 20 mg Other

Indications